Graft versus Host Disease (GVHD) is one of the major complications associated with transplantation. It is caused by donor T cells, which recognize the genetically dissimilar recipient and therefore attack the hosts body cells. At present there is no effective therapy available. We offer a simple method, whereby the transplant once is treated ex vivo with a well known substance prior to transplantation. For that only a very low concentration of the substance and a short incubation time are used. Remarkably, GVHD is reduced significantly. Due to the ex vivo treatment no side effects are expected.
Further information: PDF
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Phone: +49 (0)391/8 10 72 20
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy